Evidence map›Paper›PMID 38256428›Full record

ReviewMedicina (Kaunas, Lithuania)2024

Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice.

Laura Lopez-Gonzalez, Alicia Sanchez Cendra, Cristina Sanchez Cendra, Eduardo David Roberts Cervantes, Javier Cassinello Espinosa, Tatiana Pekarek, Oscar Fraile-Martinez, Cielo García-Montero, Ana María Rodriguez-Slocker, Laura Jiménez-Álvarez and 7 more

Open access · goldAbstract readReview
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
23.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Spatial and Proteolytic Determinants of Therapeutic Potential in HER2-Low Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Spiegelmer Aptamers: Innovative Approach in Breast Cancer.Breast cancer : basic and clinical research · 2026
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Laura Lopez-GonzalezDepartment of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcala de Henares, Spain.
Alicia Sanchez CendraOncology Service, Guadalajara University Hospital, 19002 Guadalajara, Spain.ORCID 0009-0004-8868-1660
Cristina Sanchez CendraOncology Service, Guadalajara University Hospital, 19002 Guadalajara, Spain.
Eduardo David Roberts CervantesOncology Service, Guadalajara University Hospital, 19002 Guadalajara, Spain.
Javier Cassinello EspinosaOncology Service, Guadalajara University Hospital, 19002 Guadalajara, Spain.
Tatiana PekarekDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcala de Henares, Spain.
Oscar Fraile-MartinezRamón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0002-4494-6397
Cielo García-MonteroRamón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0001-6016-7855
Ana María Rodriguez-SlockerDepartment of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcala de Henares, Spain.
Laura Jiménez-ÁlvarezDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcala de Henares, Spain.
Luis G GuijarroRamón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.
Soledad Aguado-HencheDepartment of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcala de Henares, Spain.ORCID 0000-0003-2188-3618
Jorge MonserratRamón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0003-1775-4645
Melchor Alvarez-MonRamón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0003-1309-7510
Leonel PekarekRamón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0002-5966-9003
Miguel A OrtegaRamón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0003-2588-1708
Raul Diaz-PedreroDepartment of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcala de Henares, Spain.ORCID 0000-0003-0412-939X
Universidad de Alcalá · ESHospital Universitario de Guadalajara · ES

Funding

Comunidad de Madrid MITIC-CM
6 · The paper itself

Abstract

Breast cancer is a prevalent malignancy in the present day, particularly affecting women as one of the most common forms of cancer. A significant portion of patients initially present with localized disease, for which curative treatments are pursued. Conversely, another substantial segment is diagnosed with metastatic disease, which has a worse prognosis. Recent years have witnessed a profound transformation in the prognosis for this latter group, primarily due to the discovery of various biomarkers and the emergence of targeted therapies. These biomarkers, encompassing serological, histological, and genetic indicators, have demonstrated their value across multiple aspects of breast cancer management. They play crucial roles in initial diagnosis, aiding in the detection of relapses during follow-up, guiding the application of targeted treatments, and offering valuable insights for prognostic stratification, especially for highly aggressive tumor types. Molecular markers have now become the keystone of metastatic breast cancer diagnosis, given the diverse array of chemotherapy options and treatment modalities available. These markers signify a transformative shift in the arsenal of therapeutic options against breast cancer. Their diagnostic precision enables the categorization of tumors with elevated risks of recurrence, increased aggressiveness, and heightened mortality. Furthermore, the existence of therapies tailored to target specific molecular anomalies triggers a cascade of changes in tumor behavior. Therefore, the primary objective of this article is to offer a comprehensive review of the clinical, diagnostic, prognostic, and therapeutic utility of the principal biomarkers currently in use, as well as of their clinical impact on metastatic breast cancer. In doing so, our goal is to contribute to a more profound comprehension of this complex disease and, ultimately, to enhance patient outcomes through more precise and effective treatment strategies.

Indexed as

Breast NeoplasmsBiomarkersFemaleFollow-Up StudiesHumansNeoplasm Recurrence, LocalBiomarkersbiomarkersbreast cancerhistologicalserologicaltranslational medicine

Identifiers

PMID38256428
PMCPMC10819101
OpenAlexW4390947641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.